{"translation_price":"50","translation_doc_price":"40","child_coefficient":"1.1","transfer_price":"2.00","transfer_price_vip":"5.00","constant_transfer_price_vip":350,"constant_transfer_price":150,"constant_transfer_distanse":60,"type":"treatment","program_full_story":"<ul>\n\t<li>Initial presentation in the clinic<\/li>\n\t<li>Clinical history taking<\/li>\n\t<li>Physical examination<\/li>\n\t<li>Review of medical records<\/li>\n\t<li>Laboratory tests:\n\t<ul>\n\t\t<li>Complete blood count<\/li>\n\t\t<li>General urine analysis<\/li>\n\t\t<li>Biochemical blood test (kidney and liver function tests)<\/li>\n\t\t<li>Indicators of inflammation (CRP, ESR)<\/li>\n\t\t<li>Indicators of blood coagulation<\/li>\n\t\t<li>Immunohistochemical and genetic analysis of tumor cells (if indicated)<\/li>\n\t<\/ul>\n\t<\/li>\n\t<li>Leukapheresis, processing of T-cells and cultivation of CAR T-cells<\/li>\n\t<li>Adjuvant chemotherapy<\/li>\n\t<li>Infusion of modified CAR T-cells to a patient<\/li>\n\t<li>Control examinations<\/li>\n\t<li>Cost of essential medicines and materials<\/li>\n\t<li>Nursing services<\/li>\n\t<li>Full hospital accommodation<\/li>\n\t<li>Explanation of future recommendations<\/li>\n<\/ul>\n<div class=\"program_indications_for_surgery\"><h4>Indications<\/h4><ul>\n\t<li>Acute myeloid leukemia (AML) that is resistant to the conventional therapy<\/li>\n<\/ul>\n<\/div><div class=\"program_how_program_going mt-4\"><h4>How program is carried out<\/h4><p><strong>Days 1-2<\/strong>. Initial presentation at the clinic. The doctor collects the patient's medical history, looks at his medical records and previous examinations. Special attention is paid to previous cancer treatments and their results, since CAR T-cell therapy is indicated only if the conventional treatment protocols are ineffective. Based on the results of the consultation, the doctor administers the examination, which includes a complete blood count with white blood cell count, assessment of liver and kidney function, immunohistochemical and genetic analysis of tumor cells (if indicated) and other studies.<\/p>\n\n<p><strong>Day 3<\/strong>. Collecting patient’s blood. During the leukapheresis procedure, doctors harvest at least 100 million T-cells, which will subsequently undergo gene modification. If there are certain clinical reasons, and the patient needs to postpone the subsequent stages of CAR T-cell therapy, the harvested T-cells undergo the procedure of cryoconservation. If the patient is able to continue treatment immediately, then the harvested T-cells are transferred to the laboratory.<\/p>\n\n<p><strong>Days 4-12<\/strong>. Processing and gene modification of the T-cells pool lasts 7-10 days. During this time, the patient is receiving immunosuppressive chemotherapy drugs. The chemotherapy is aimed at suppressing the patient's own immune system, which will allow CAR T-cells to fight the tumor more effectively.<\/p>\n\n<p><strong>Day 13<\/strong>. Manufactured CAR T-cells are tested for the microbiological safety and functional activity. After the successful testing completion, the solution with CAR T-cells is administered to the patient intravenously.<\/p>\n\n<p><strong>Day 14 and other days<\/strong>. Control examination and further medical supervision in the hospital are carried out. If there are no side effects of CAR T-cell therapy, a stable tendency towards normalization of blood count is observed and the patient has stable general health condition, the patient is discharged from the hospital. Before the discharge, the patient receives the detailed recommendations for further follow-up during the disease remission.<\/p>\n<\/div><div class=\"program_required_documents mt-4\"><h4>Required documents<\/h4><ul>\n\t<li>Complete blood count with white blood cell count<\/li>\n\t<li>Biochemical blood test (renal and liver function tests), if available<\/li>\n\t<li>Bone marrow biopsy results<\/li>\n\t<li>CT scan, if available<\/li>\n<\/ul>\n<\/div>","program_full_story_crm":"<ul>\n\t<li>Initial presentation in the clinic<\/li>\n\t<li>Clinical history taking<\/li>\n\t<li>Physical examination<\/li>\n\t<li>Review of medical records<\/li>\n\t<li>Laboratory tests:\n\t<ul>\n\t\t<li>Complete blood count<\/li>\n\t\t<li>General urine analysis<\/li>\n\t\t<li>Biochemical blood test (kidney and liver function tests)<\/li>\n\t\t<li>Indicators of inflammation (CRP, ESR)<\/li>\n\t\t<li>Indicators of blood coagulation<\/li>\n\t\t<li>Immunohistochemical and genetic analysis of tumor cells (if indicated)<\/li>\n\t<\/ul>\n\t<\/li>\n\t<li>Leukapheresis, processing of T-cells and cultivation of CAR T-cells<\/li>\n\t<li>Adjuvant chemotherapy<\/li>\n\t<li>Infusion of modified CAR T-cells to a patient<\/li>\n\t<li>Control examinations<\/li>\n\t<li>Cost of essential medicines and materials<\/li>\n\t<li>Nursing services<\/li>\n\t<li>Full hospital accommodation<\/li>\n\t<li>Explanation of future recommendations<\/li>\n<\/ul>\n<div class=\"program_indications_for_surgery\"><h4>Indications<\/h4><ul>\n\t<li>Acute myeloid leukemia (AML) that is resistant to the conventional therapy<\/li>\n<\/ul>\n<\/div><div class=\"program_how_program_going mt-4\"><h4>How program is carried out<\/h4><p><strong>Days 1-2<\/strong>. Initial presentation at the clinic. The doctor collects the patient's medical history, looks at his medical records and previous examinations. Special attention is paid to previous cancer treatments and their results, since CAR T-cell therapy is indicated only if the conventional treatment protocols are ineffective. Based on the results of the consultation, the doctor administers the examination, which includes a complete blood count with white blood cell count, assessment of liver and kidney function, immunohistochemical and genetic analysis of tumor cells (if indicated) and other studies.<\/p>\n\n<p><strong>Day 3<\/strong>. Collecting patient’s blood. During the leukapheresis procedure, doctors harvest at least 100 million T-cells, which will subsequently undergo gene modification. If there are certain clinical reasons, and the patient needs to postpone the subsequent stages of CAR T-cell therapy, the harvested T-cells undergo the procedure of cryoconservation. If the patient is able to continue treatment immediately, then the harvested T-cells are transferred to the laboratory.<\/p>\n\n<p><strong>Days 4-12<\/strong>. Processing and gene modification of the T-cells pool lasts 7-10 days. During this time, the patient is receiving immunosuppressive chemotherapy drugs. The chemotherapy is aimed at suppressing the patient's own immune system, which will allow CAR T-cells to fight the tumor more effectively.<\/p>\n\n<p><strong>Day 13<\/strong>. Manufactured CAR T-cells are tested for the microbiological safety and functional activity. After the successful testing completion, the solution with CAR T-cells is administered to the patient intravenously.<\/p>\n\n<p><strong>Day 14 and other days<\/strong>. Control examination and further medical supervision in the hospital are carried out. If there are no side effects of CAR T-cell therapy, a stable tendency towards normalization of blood count is observed and the patient has stable general health condition, the patient is discharged from the hospital. Before the discharge, the patient receives the detailed recommendations for further follow-up during the disease remission.<\/p>\n<\/div>","is_ambulant":"0","bh_fee":"0","only_for_children":"0","no_service":"0","with_prepayment":"1","show_calculator":"1","paket_type":"1","btn_type":"0","clinic_icon":"600567cd28708.jpg","city":"Giessen","clinic_site":"www.ukgm.de","department_recommend":"1","country":"Germany","country_id":"1","clinic_name":"University Hospital Giessen UKGM","cinic_name":"University Hospital Giessen UKGM","department_id":"1043","duration":"21","direction":"Hematology","min_duration":0,"clinic_id":"22","paketPrice":36000,"paket":"<ul>\n <li>Interpreter up to 80 hours<\/li>\n <li>Translation up to 15 pages<\/li>\n <li>Visa support<\/li>\n<\/ul>","title":"Treatment of acute myeloid leukemia (AML) with CAR T-cell therapy","price":{"val":495716,"type":"val"},"price_surcharge":0,"price_surcharge_clear":0,"extra_service_clinic":[{"id":"need_to_use_head_doctor","title":"Treatment by leading experts","type":"val","val":null,"req":0},{"id":"1_person_room","title":" Single room (whole period)","parent":"duration","type":"count_val","val":"130.00"},{"id":"2_person_room","title":" double room (whole period)","parent":"duration","type":"count_val","val":"70.00"},{"id":"attendant_place","title":"Accommodation for the accompanying person ","parent":"duration","type":"count_val","val":"90.00"}],"extra_service":[],"translation_hours":"0","translation_doc_count":null,"roads":[{"id":"6","distance":"75","airport_title":"Frankfurt a.M."},{"id":"4","distance":"150","airport_title":"Duesseldorf"},{"id":"7","distance":"199","airport_title":"Cologne-Bonn"}],"pakets":[],"lang":{"day":"Day","days":"days","ambulatory":"Outpatient","stationaryProgram":"Inpatient"}}
Treatment of acute myeloid leukemia (AML) with CAR T-cell therapy in University Hospital Giessen UKGM
Biochemical blood test (kidney and liver function tests)
Indicators of inflammation (CRP, ESR)
Indicators of blood coagulation
Immunohistochemical and genetic analysis of tumor cells (if indicated)
Leukapheresis, processing of T-cells and cultivation of CAR T-cells
Adjuvant chemotherapy
Infusion of modified CAR T-cells to a patient
Control examinations
Cost of essential medicines and materials
Nursing services
Full hospital accommodation
Explanation of future recommendations
Indications
Acute myeloid leukemia (AML) that is resistant to the conventional therapy
How program is carried out
Days 1-2. Initial presentation at the clinic. The doctor collects the patient's medical history, looks at his medical records and previous examinations. Special attention is paid to previous cancer treatments and their results, since CAR T-cell therapy is indicated only if the conventional treatment protocols are ineffective. Based on the results of the consultation, the doctor administers the examination, which includes a complete blood count with white blood cell count, assessment of liver and kidney function, immunohistochemical and genetic analysis of tumor cells (if indicated) and other studies.
Day 3. Collecting patient’s blood. During the leukapheresis procedure, doctors harvest at least 100 million T-cells, which will subsequently undergo gene modification. If there are certain clinical reasons, and the patient needs to postpone the subsequent stages of CAR T-cell therapy, the harvested T-cells undergo the procedure of cryoconservation. If the patient is able to continue treatment immediately, then the harvested T-cells are transferred to the laboratory.
Days 4-12. Processing and gene modification of the T-cells pool lasts 7-10 days. During this time, the patient is receiving immunosuppressive chemotherapy drugs. The chemotherapy is aimed at suppressing the patient's own immune system, which will allow CAR T-cells to fight the tumor more effectively.
Day 13. Manufactured CAR T-cells are tested for the microbiological safety and functional activity. After the successful testing completion, the solution with CAR T-cells is administered to the patient intravenously.
Day 14 and other days. Control examination and further medical supervision in the hospital are carried out. If there are no side effects of CAR T-cell therapy, a stable tendency towards normalization of blood count is observed and the patient has stable general health condition, the patient is discharged from the hospital. Before the discharge, the patient receives the detailed recommendations for further follow-up during the disease remission.
Required documents
Complete blood count with white blood cell count
Biochemical blood test (renal and liver function tests), if available
Bone marrow biopsy results
CT scan, if available
Service
Price from:
Type of program :
Price for 1 day:
Expected duration of the program:
The minimum duration of the program:
Select
You may also book:
Hospital directly:
Saving:
BookingHealth Price from:
About the department
The Department of Oncology, Hematology and Palliative Care at the University Hospital Giessen UKGM offers all the options of modern medicine for the treatment of patients with the pathologies in these fields. Specialization covers the treatment of cancer of the internal organs, blood cancer, symptomatic treatment of progressive incurable diseases. Other focuses of the department are intensive care medicine and special pain therapy. To achieve successful and long-term results, the clinical practice is based on the use of effective classic and innovative treatment methods. The department is headed by Prof. Dr. Dr. med. Friedrich Grimminger.
The department's oncologists take care of the health of patients with malignant diseases of all organs. The department is part of the Interdisciplinary Cancer Center, within which all experts from related fields work for the benefit of patients. The individual and optimal treatment regimens are developed at interdisciplinary tumor boards. The treatment is carried out in accordance with national and international protocols of professional societies. The patients with terminal stages of the disease are provided with all the necessary palliative care measures, which helps to alleviate symptoms and improve the quality of life.
Another department’s priority is the treatment of patients with malignant diseases of the hematopoietic and lymphatic systems. Of particular interest is the treatment of malignant lymphomas, acute and chronic leukemias and myeloproliferative disorders. The spectrum is also complemented by therapy for blood-clotting disorders, such as immune thrombocytopenia.
The department's range of medical services includes:
Diagnostics and treatment of oncological diseases of internal organs
Respiratory system cancers
Lung cancer
Pleural cancer
Gastrointestinal cancers
Bowel cancer
Rectal cancer
Esophageal carcinoma
Stomach cancer
Pancreatic cancer
Liver cancer
Head and neck tumors
Primary brain tumors
Tumors of the lips, mouth and oropharynx
Laryngeal cancer
Thyroid cancer
Gynecological tumors
Breast cancer
Ovarian cancer
Uterine cancer
Cervical cancer
Urological tumors
Prostate cancer
Kidney cancer
Bladder cancer
Rare tumors
Sarcomas
Melanomas
Diagnostics and treatment of hematological diseases
Acute lymphocytic leukemia
Acute myeloid leukemia
Amyloidosis
Aplastic anemia
Chronic lymphocytic leukemia
Chronic myeloid leukemia
Essential thrombocythemia
Hairy cell leukemia
Hemoglobinopathies
Hemolytic anemia
Hodgkin's lymphoma
Immune thrombocytopenia
Multiple myeloma
Myelodysplastic syndrome
Non-Hodgkin’s lymphoma
Polycythemia vera
Osteomyelosclerosis
Palliative care for patients at the terminal stage of cancer aimed at alleviating symptoms and improving quality of life
Other medical services
Curriculum vitae
Prof. Friedrich Grimminger studied medicine at the Justus Liebig University Giessen. He also completed a semester at the British Universities of Newcastle and Edinburgh (Chemistry and Biology). In 1989, he received his doctorate in Human Medicine, and in 1990 also received a diploma in Biology. Two years later, he had his habilitation in Human Medicine at the Justus Liebig University Giessen. In 1994, Prof. Grimminger had his board certification in Internal Medicine with a focus on Pulmonology, Oncology, Intensive Care, Palliative Care and Pain Therapy. He is a Honorary Professor at the Universities of Kent (Canterbury, UK) and Texas, USA.
Photo of the doctor: (c) UKGM - Universitätsklinikum Gießen und Marburg GmbH
About hospital
The University Hospital Giessen UKGM positions itself as an ultramodern medical facility with outstanding quality of medical care. The hospital presents almost all areas of medicine, ranging from ophthalmology to traumatology and dentistry. The priorities of the hospital’s activities include surgery, neurosurgery, oncology, nephrology with kidney transplantation and pediatric medicine.
The hospital is the third largest in Germany. Every year, more than 436,000 patients are treated in two locations of the hospital (Giessen and Marburg): 342,000 outpatients and 94,000 inpatients. The medical facility is the first privatized university hospital in the country.
The hospital staff is engaged not only in clinical practice, but also in research activities on the basis of the Faculty of Medicine at Justus Liebig University Giessen and Philipps University of Marburg, which contributes to a significant contribution to the development of modern medicine. During the many years of productive work on the development of new diagnostic and treatment methods, the hospital’s doctors managed to make many significant discoveries.
The hospital enjoys an excellent reputation in Germany and far beyond its borders. It managed to gain such credibility thanks to the high competence of doctors, advanced equipment, high-quality medical service and care.
Photo: (c) depositphotos
Accommodation in hospital
Patients rooms
The patients of the University Hospital Giessen UKGM live in comfortable rooms made in a modern design and light colors. Each room has an ensuite bathroom with shower and toilet. The standard room furnishing includes an automatically adjustable bed, a bedside table, a wardrobe, a table and chairs for receiving visitors, a TV, a telephone.
Meals and Menus
The patients of the hospital are offered balanced, healthy three meals a day: buffet breakfast, lunch and dinner. The private kitchen, certified according to DIN EN ISO 9001:2000, is responsible for providing patients with food and drinks.
If for some reason you do not eat all foods, you will be offered an individual menu. The hospital also has a cafeteria with a large assortment of hot and cold drinks, snacks and desserts.
Further details
Standard rooms include:
Toilet
Shower
Wi-Fi
TV
Television
All patient rooms are equipped with TV sets. If you have some questions, please contact medical personnel.
Religion
Religious services can be provided upon request.
Accompanying person
During an inpatient program, an accompanying person can stay with you in a patient room or in a hotel of your choice.
Hotel
During the outpatient program, you can stay at the hotel of your choice. Our managers will help you to choose the most suitable option.
Select your currency:
Your guarantee
One year of support after the treatment
Insurance to cover unforeseen expenses arising from complications during and 48 months after treatment (coverage up to 200,000 €)
Reduced costs by 40-70% (contracts with Hospitals)
In addition, we are the only TÜV-certified company with an ISO 9001:2015 certificate